Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets and Stendra
Determining the interaction of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets and Stendra and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using avanafil together with ritonavir is not recommended. Combining these medications may significantly increase the blood levels of avanafil. This may increase the risk of serious side effects such as low blood pressure; fainting; visual disturbances including loss of vision; ringing in the ears; hearing loss; and priapism (prolonged and painful erection unrelated to sexual activity). Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme. In 15 healthy male volunteers, administration of a single 50 mg dose of avanafil following pretreatment with the potent CYP450 3A4 inhibitor ketoconazole (400 mg once daily for 5 days) increased avanafil peak plasma concentration (Cmax) and systemic exposure (AUC) by approximately 3-fold and 13-fold, respectively, compared to administration of avanafil alone. Likewise, when a single 50 mg dose of avanafil was administered to 14 healthy male volunteers treated with ritonavir (600 mg twice daily for 5 days), avanafil Cmax increased by 2.4-fold and AUC increased by 13-fold. Both ketoconazole and ritonavir prolonged the half-life of avanafil to approximately 9 hours, from a normal of 5 hours.
MANAGEMENT: Concomitant use of avanafil with potent CYP450 3A4 inhibitors should generally be avoided.
- "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.
Generic Name: dasabuvir / ombitasvir / paritaprevir / ritonavir
Brand name: Viekira XR, Viekira Pak
Synonyms: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Sterapred
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Sterapred DS
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Sterile Saline Diluent Tip-Lok Syringe
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Stieva-A Cream Forte Topical
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Stieva-A Cream Topical
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Stieva-A Gel Topical
- Stendra-Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets
- Stendra-Omeclamox-Pak
- Stendra-Omega-3 Fatty Acid Capsules
- Stendra-Omega-3 Fatty Acids
- Stendra-Omega-3 polyunsaturated fatty acids
- Stendra-Omega-3-acid ethyl esters